口服孟魯司特與鼻用氟替卡松癸酸酯在減輕兒童睡眠呼吸障礙嚴重度的療效比較：一項隨機臨床試驗

// The efficacy of oral montelukast versus intranasal fluticasone furoate in reducing the severity of pediatric sleep-disordered breathing: A randomized clinical trial

本研究比較口服孟魯司特（抗發炎藥物）與鼻用氟替卡松（皮質類固醇）對腺樣體與扁桃腺肥大兒童睡眠呼吸障礙的改善效果｜兩者均顯著減輕症狀及腺樣體大小，惟僅孟魯司特能縮小扁桃腺｜建議扁桃腺肥大時優先使用孟魯司特，腺樣體肥大則適合氟替卡松｜此類藥物或成手術替代選項，但長期安全性仍待進一步研究驗證。

// This study compared oral montelukast and intranasal fluticasone furoate for reducing sleep-disordered breathing in children with adenotonsillar hypertrophy. Both treatments significantly improved symptoms and adenoid size, but only montelukast reduced tonsillar size. Montelukast may be preferred when tonsillar hypertrophy is present, while fluticasone furoate suits adenoid hypertrophy. These medications could be alternatives to surgery, though long-term effects require further research.

Published 2026年8月18日